This week we’re joined by Gregory Kellog of Fulgent Genetics. In this episode we explore pharmacogenomics. Gregory is the Director of Genetic Counseling at Fulgent Genetics, a technology-based genetic testing company. Prior to serving as the director, Gregory served as the Genetic Counseling Manager at Fulgent, and worked in various roles for other genetic testing companies over the last 7 years including Recombine, Phosphorus, and Illumina. He completed his master of science in human genetics and genetic counseling at Stanford University School of Medicine. On This Episode We Discuss: What is pharmacogenomics? Aspects of metabolizing drugs that pharmacogenomic screening evaluates (i.e. Toxicity, Lack of Efficacy, Hypersensitivity) How pharmacogenomics testing decreases the risk of adverse drug reactions Genetic counseling for pharmacogenomics Roadblocks (ethical, social, legal, privacy) impacting widespread use of pharmacogenomic testing Picture Genetics’ PGx kit You can check out the CPIC Guidelines and the FDA Table of PGx Associations that Greg mentioned during the episode. Discover if the medication you take might be affected by your genetics. See the full list of genes evaluated by Picture Genetics’ PGx test here. Learn more about Picture Genetics on their website, and follow them on LinkedIn, Twitter, Facebook, and Instagram, and keep up with our guest, Gregory Kellog, on LinkedIn. Stay tuned for the next new episode of DNA Today on March 11, 2022 where we’ll be chatting with Brian Shirts from ConnectMyVariant about the Hereditary Cancer Variant Network! In the meantime, you can binge over 170 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. All episodes in 2021 are also recorded with video which you can watch on our YouTube channel. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to [email protected]. Have you heard of the Blueprint Genetics My Retina Tracker Program? This program offers eligible patients in the US no-cost comprehensive genetic testing and counseling for their inherited retinal degeneration. The My Retina Tracker Program Panel includes 351 genes, mitochondrial DNA, and non-coding variant assessment. Stay tuned for our interview with Blueprint Genetics about the My Retina Tracker Program and the patient registry on a future episode of DNA Today. In the meantime, you can learn more at BlueprintGenetics.com. (SPONSORED) PerkinElmer Genomics is a global leader in genetic testing focusing on rare diseases, inherited disorders, newborn screening, and hereditary cancer. Testing services support the full continuum of care from preconception and prenatal to neonatal, pediatric, and adult. Testing options include sequencing for targeted genes, multiple genes, the whole exome or genome, and copy number variations. Using a simple saliva or blood sample, PerkinElmer Genomics answers complex genetic questions that can proactively inform patient care and end the diagnostic odyssey for families. Learn more at PerkinElmerGenomics.com. (SPONSORED)

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related